The Biotech Religion Invaded by Investor Skeptics
It has taken months for biotech's March madness to calm back into something like sanity, doing so in the context of Nasdaq's overall downward spiral. But if there was one lesson to the volume of recent financings it was this: the big can get bigger; the small-and the early-stage-should be just a teeny bit worried. The large and highly valued companies, particularly those with drugs on or about to be on the market can raise money easily. But new discovery-stage offerings have had trouble--like Rigel's. IPO buyers have instead opted for the apparently lower-risk, faster-return businesses of nearer-term companies like drug-delivery and service firms.
You may also be interested in...
There are many ways start-ups can lower the risks of doing business in the current climate. Amphora's approach will likely include working for hire to cool cash burn while building relationships with skittish clients; leveraging assets that have ripened beyond the research phase; and helping customers reduce the risks they confront.
There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.
Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure
A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.